7/23/2023 0 Comments Abpn folio![]() Physician Continuing Medical Education Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 credit™. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the Lewy Body Dementia Association. Jointly provided by Postgraduate Institute of Medicine and Lewy Body Dementia Association Northwestern University Feinberg School of Medicine Shirley Ryan Ability Lab, Parkinson’s Disease and Movement Disorders ![]() This activity has been designed to meet the educational needs of healthcare providers involved in the care of patients with Lewy body dementia. Webinar #3: Impact of COVID-19 in those with LBD Webinar #2: Understanding Current Research on Virtual Assessment Webinar #1: The approach to clinical care via telemedicine The Lewy Body Dementia Association (LBDA), the Research Center of Excellence (RCOE) program, and the ISTAART DLB Professional Interest Area Executive Committee have, therefore, collectively identified a need for a series of webinars that address the topic of virtual care in LBD during the COVID-19 pandemic and beyond. While the call for telemedicine during COVID-19 is clear, it is less clear how in-office diagnosis and care translates to virtual care in this population. ![]() Those with LBD represent a particularly vulnerable population to the complications of COVID-19 given advanced age and the clinical features inherent to LBD. This article provides information on potentially important issues related to the off-label treatment approach that should be considered to help ensure patient safety.The COVID-19 pandemic necessitated transition of care to telemedicine due to public health concerns. While ketamine may be beneficial to some patients with mood disorders, it is important to consider the limitations of the available data and the potential risk associated with the drug when considering the treatment option.Ĭonclusions and Relevance The suggestions provided are intended to facilitate clinical decision making and encourage an evidence-based approach to using ketamine in the treatment of psychiatric disorders considering the limited information that is currently available. Observations This review and consensus statement provides a general overview of the data on the use of ketamine for the treatment of mood disorders and highlights the limitations of the existing knowledge. Despite the relatively small sample sizes, lack of longer-term data on efficacy, and limited data on safety provided by these studies, they have led to increased use of ketamine as an off-label treatment for mood and other psychiatric disorders. Importance Several studies now provide evidence of ketamine hydrochloride’s ability to produce rapid and robust antidepressant effects in patients with mood and anxiety disorders that were previously resistant to treatment.
0 Comments
Leave a Reply. |